Table 2.
Comparison of patients in the pre-Z11 and post-Z11 groups.
| Clinical and pathologic variables | Pre-Z11 (52 mo) n = 279 |
Post-Z11 (34 mo) n = 191 |
P value |
|---|---|---|---|
| Age (y) | 58.6 ± 13.9 | 56.7 ± 13.2 | 0.14 |
| Mean ± standard dev | |||
| Race | 0.73 | ||
| White | 230 (82.4%) | 152 (79.6%) | |
| Black | 42 (15.1%) | 33 (17.2%) | |
| Other | 7 (2.5%) | 6 (3.1%) | |
| Laterality | 0.45 | ||
| Right | 138 (49.5%) | 87 (45.5%) | |
| Left | 141 (50.5%) | 104 (54.5%) | |
| Procedure | 0.048 | ||
| WLE* + ALND | 122 (43.7%) | 62 (33.0%) | |
| MRM | 134 (48.0%) | 111 (58.1%) | |
| ALND alone | 23 (8.2%) | 18 (9.4%) | |
| Level | 0.85 | ||
| II | 260 (93.2%) | 179 (93.7%) | |
| III | 19 (6.8%) | 12 (6.3%) | |
| Path stage | 0.13 | ||
| I | 16 (5.8%) | 10 (5.2%) | |
| II | 153 (54.8%) | 91 (47.6%) | |
| III | 104 (37.4%) | 89 (46.6%) | |
| IV | 6 (2.2%) | 1 (0.5%) | |
| Tumor size (cm) | 2.91 ± 2.72 | 3.19 ± 2.68 | 0.20 |
| # nodes resected | 19.86 ± 7.66 | 19.53 ± 8.66 | 0.46 |
| # nodes positive | 3.62 ± 4.81 | 4.52 ± 5.24 | 0.06 |
| Histology | 0.14 | ||
| DCIS | 0 (0%) | 1 (0.5%) | |
| Invasive ductal | 225 (80.6%) | 158 (82.7%) | |
| Invasive lobular | 37 (13.3%) | 24 (12.6%) | |
| Inflammatory | 14 (5.0%) | 3 (1.6%) | |
| Other | 3 (1.1%) | 5 (2.6%) | |
| ER status | 0.92 | ||
| Negative | 73 (26.2%) | 49 (25.7%) | |
| Positive | 206 (73.8%) | 142 (74.3%) | |
| PR status | 0.28 | ||
| Negative | 101 (36.2%) | 59 (30.9%) | |
| Positive | 178 (63.8%) | 130 (68.1%) | |
| HER-2 status | 1.00 | ||
| Negative | 238 (85.3%) | 162 (84.8%) | |
| Positive | 39 (14.0%) | 26 (13.6%) | |
| Unknown | 2 (0.01%) | 2 (0.01%) |
MRM = modified radical mastectomy; DCIS = ductal carcinoma in situ; ER = estrogen receptor; PR = progesterone receptor.
*
WLE = wide local excision, lumpectomy, partial mastectomy.